An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Netakimab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms PLANETA
- Sponsors Biocad
- 07 May 2019 Results published in the Biocad Media Release.
- 07 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2018 New trial record